FAQs
Based on analyst ratings, High Tide's 12-month average price target is $4.50. High Tide has 101.79% upside potential, based on the analysts' average price target. High Tide has a consensus rating of Moderate Buy which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
What is the target price for Hitide? ›
Based on analysts offering 12 month price targets for HITI in the last 3 months. The average price target is $4.69 with a high estimate of $6.258974235 and a low estimate of $3.313574595.
Is HITI undervalued? ›
The intrinsic value of one HITI stock under the Base Case scenario is 4.42 USD. Compared to the current market price of 2.04 USD, High Tide Inc is Undervalued by 54%.
Should I invest in high tide? ›
High Tide's analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
Why is Shockwave stock dropping? ›
What happened. Shares of Shockwave Medical (SWAV) were down 9.5% as of 11:35 a.m. ET Tuesday, according to data provided by S&P Global Market Intelligence, after the company announced mixed second-quarter 2023 results relative to Wall Street's expectations.
Does Hiti pay dividends? ›
Does High Tide pay dividends? No.
What is the target price for NVMI? ›
The average price target for Nova Measuring is $258.25. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $273.00 ,the lowest forecast is $240.00. The average price target represents 24.54% Increase from the current price of $207.37.
What is the target price for Ubsi? ›
Stock Price Targets
| High | $42.97 |
|---|
| Median | $33.64 |
| Low | $24.32 |
| Average | $32.69 |
| Current Price | $29.79 |
Stock Price Targets
| High | $5.20 |
|---|
| Median | $3.10 |
| Low | $1.00 |
| Average | $3.10 |
| Current Price | $0.4373 |
The ownership structure of High Tide (HITI) stock is a mix of institutional, retail and individual investors. Approximately 8.13% of the company's stock is owned by Institutional Investors, 56.02% is owned by Insiders and 35.85% is owned by Public Companies and Individual Investors.
Most overvalued US stocks
| Symbol | RSI (14) | Price |
|---|
| SRBK D | 79.63 | 10.39 USD |
| NUVL D | 79.38 | 112.17 USD |
| AXGN D | 79.37 | 14.29 USD |
| CRVS D | 79.19 | 5.78 USD |
29 more rowsHiTi Digital, Inc., a professional manufacturer and supplier of digital photo products and services, is well known for high-quality and innovative technology.
Will high tide stock go up? ›
The Wall Street analyst predicted that High Tide's share price could reach $4.50 by Mar 25, 2025. The average High Tide stock price prediction forecasts a potential upside of 101.79% from the current HITI share price of $2.23. What is HITI's Earnings Per Share (EPS) forecast for 2024-2025?
Is high tide a good company? ›
High Tide is a vibrant workplace with a friendly and relaxed environment. The team is supportive, and there's a strong focus on creating a positive customer experience. It's a great place to start if you're interested in the retail cannabis industry, with opportunities to learn and grow.
Is Hiti a sell? ›
High Tide Inc. (HITI) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.)
Will First Wave Biopharma stock go up? ›
Based on analyst ratings, First Wave Bio's 12-month average price target is $36.00.
Is HITI a sell? ›
High Tide Inc. (HITI) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.)
Will American lithium stock go up? ›
Based on short-term price targets offered by four analysts, the average price target for American Lithium Corp. comes to $2.39. The forecasts range from a low of $1.09 to a high of $3.72. The average price target represents an increase of 624.24% from the last closing price of $0.33.
Is Sutro Biopharma a good stock to buy? ›
Sutro Biopharma Inc has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings. The average price target for Sutro Biopharma Inc is $10.43. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
